-continued

<400> SEQUENCE: 65

accctccaat tgtcaggtaa tttccttcac ggtc 34

1.-31. (canceled)

32. A method of treatment of an inflammatory disease, comprising administering to a human in need thereof a therapeutically effective amount of a Granulocyte-macrophage colony stimulating factor (GM-CSF) binding protein comprising:

(a) a variable heavy (VH) region comprising a sequence at least 95% identical to the sequence of SEQ ID NO: 20; and

(b) a variable light (VL) region comprising a sequence at least 95% identical to the sequence of SEQ ID NO: 40.

33. The method of claim 32, wherein the inflammatory disease is rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis, or shock.

34. The method of claim 33, wherein the inflammatory disease is rheumatoid arthritis.

35. The method of claim 32, wherein the GM-CSF binding protein is an isolated antibody.

36. The method of claim 35, wherein the isolated antibody is an IgG.

37. The method of claim 36, wherein the IgG is an IgG1.

38. The method of claim 35, wherein the isolated antibody is a synthetic human antibody.

39. The method of claim 35, wherein the VH of the isolated antibody comprises a CDR1, CDR2, and CDR3 of SEQ ID NO: 20; and the VL of the isolated antibody comprises a CDR1, CDR2, and CDR3 of SEQ ID NO: 40.

40. The method of claim 32, wherein the GM-CSF binding protein is administered subcutaneously.

41. The method of claim 32, wherein the GM-CSF binding protein is administered intravenously.

42. The method of claim 32, wherein the GM-CSF binding protein comprises:

(a) a VH region comprising the sequence of SEQ ID NO: 20; and

(b) a VL region comprising the sequence of SEQ ID NO: 40.

43. The method of claim 42, wherein the inflammatory disease is rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis, or shock.

44. The method of claim 43, wherein the inflammatory disease is rheumatoid arthritis.

45. The method of claim 42, wherein the GM-CSF binding protein is an isolated antibody.

46. The method of claim 45, wherein the isolated antibody is an IgG.

47. The method of claim 46, wherein the IgG is an IgG1.

48. The method of claim 45, wherein the isolated antibody is a synthetic human antibody.

49. The method of claim 42, wherein the GM-CSF binding protein is administered subcutaneously.

50. The method of claim 42, wherein the GM-CSF binding protein is administered intravenously.

51. A method of treatment of rheumatoid arthritis, comprising administering to a human in need thereof a therapeutically effective amount of a Granulocyte-macrophage colony stimulating factor (GM-CSF) binding protein which is an isolated synthetic human IgG1 antibody comprising:

(a) a VH region comprising the sequence of SEQ ID NO: 20; and

(b) a VL region comprising the sequence of SEQ ID NO: 40.

* * * * *